Edmolin.com

Informed Today Influential Tomorrow

Medicine

PSB industries highlights siloxane removal packaged skid

PSB Industries, a specialist in the design and fabrication of systems for dehydrating and purifying gasses and liquids, is highlighting its Siloxane Removal packaged skid, an advanced gas purification system.

This solution is engineered to meet the rigorous demands of gas processing across diverse industries. The Siloxane Removal packaged skid offers a dependable method for eliminating siloxanes and protecting valuable equipment, making it an essential component for facilities seeking to maintain operational reliability and meet purity standards. 

The system features a proprietary sacrificial carbon-based media that removes siloxanes from gas streams at parts-per-million levels down to undetectable concentrations. This high removal efficiency prevents silica deposits and contamination, safeguarding engines, turbines, burners, and pipelines from damage, reducing maintenance, and minimising costly downtime. It also protects expensive downstream deoxygenation catalysts and membranes by removing harmful species from the gas, which prevents OPEX-intensive catalyst and membrane cartridge replacement.  

The Siloxane Removal system is engineered for flexible operation, with flow capacities ranging from 50 to 10,000 standard cubic feet per minute and operating pressures from 50 to 800 pounds per square inch gauge. This versatility allows seamless integration into a wide variety of industrial processes and ensures consistent performance across different applications. 

A key feature of the system is its ability to maintain high removal efficiency over extended periods, which means less frequent media replacement and lower overall operating costs. The robust design ensures reliable, long-term operation, while the system’s adaptability supports both new and existing installations. The system also features a replaceable bed, allowing for easy maintenance and ensuring continuous operation by enabling the bed to be replaced with fresh media as needed. An optional particulate filter is available, which protects downstream processes by filtering out particulates and enhancing overall system reliability. 

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *

Medicine

GSK’s RSV Vaccine Accepted Under Priority Review in USGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under priority review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. If approved, GSK’s RSV vaccine would be the first vaccine available to help protect this population. Arexvy is currently approved in the US in adults aged 60 and over for the prevention of lower respiratory tract disease (LRTD) caused by RSV. The application is supported by positive results from a phase III trial [NCT05590403]4 evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to underlying medical conditions. GSK used a Priority Review Voucher to reduce the US FDA review period of a supplemental Biologics License Application (sBLA) by four months. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is 7 June 2024. The burden of RSV disease in adults is likely to be underestimated due to lack of awareness, a lack of standardised testing, and under-detection in surveillance studies.5 People with underlying medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, chronic heart failure6 and diabetes,7 are at increased risk for RSV disease. RSV can exacerbate these conditions and lead to pneumonia, hospitalisation, or death.8